Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Verrica Pharmaceuticals, Inc.

https://verrica.com/

Latest From Verrica Pharmaceuticals, Inc.

Norway’s Lytix Licenses Lead Asset To Verrica For Skin Cancers

Norwegian biotech Lytix says a licensing deal with Verrica in dermatologic oncology indications gives it commercial validity – and leaves options open in other cancer areas.

Deals Cancer

Asia Deal Watch: Perceptive Launches LianBio With “China-Centric” Strategy

Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.

Deals Business Strategies

US FDA Picks Up The Pace Of Complete Response Letters Over June And July

The year began with an unusually low number of CRLs, but a recent burst of non-approval actions suggests a COVID-19 effect.

Complete Response Letters US FDA Performance Tracker

Verrica’s Molluscum Product Set Back By FDA Usage Questions

Verrica got a complete response rather than approval for its drug/device combo for molluscum, but says the FDA only needs additional information on product changes for safe usage by clinicians.

Complete Response Letters Drug Approval Standards
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register